June 2014

In this issue of Cardiology Review, we cover several burning topics of interest to clinicians.

The first wireless implantable hemodynamic monitoring system for patients with heart failure has been approved by the FDA.

The American Society of Hypertension (ASH) is the largest US professional organization dedicated to eradicating hypertension and its consequences. The following study presentations were highlights of the organization's 29th annual meeting in New York City.

AstraZeneca's Epanova (omega-3-carboxylic acids) was approved by the FDA for the treatment of adults with severe hypertriglyceridemia; two new studies support the concept that there can be too much of a good thing when it comes to exercise; and the FDA has issued a new statement recommending against the use of aspirin to prevent a first heart attack or stroke in people with no history of cardiovascular disease.

Mitral valve replacement provides a greater freedom from recurrent MR in patients with ischemic MR, but does it affect clinical outcomes?

The role of blood transfusions in patients undergoing percutaneous coronary intervention remains controversial.

Should we give digoxin another look for chronic heart failure?

The safety and efficacy of drug-eluting stents are proven in the general population, but how do they perform in women?

This meta-analysis attempts to definitively answer questions about the role of anger in cardiovascular events.

Access, delivery, and affordability-will the courts decide the best course of action or will Congress?

It is primarily the responsibility of parents, teachers, and health care professionals to be role models for the younger generation with respect to healthy eating and physical activity.